Safety and Effectiveness of BAY 43-9006 in Cancer Patients
Author Information
Author(s): Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase C G, Schwartz B, Piccart M
Primary Institution: Jules Bordet Institute, Brussels, Belgium
Hypothesis
The study aims to determine the safety profile, maximum tolerated dose, and pharmacokinetics of BAY 43-9006 in patients with advanced, refractory solid tumors.
Conclusion
BAY 43-9006 was found to be safe, well tolerated, and showed antitumor activity in patients with advanced, refractory solid tumors.
Supporting Evidence
- BAY 43-9006 was administered daily for repeated cycles of 21 days on/7 days off.
- The most frequently reported adverse events were gastrointestinal (75%), dermatologic (71%), and constitutional (68%).
- A maximum tolerated dose of 400 mg b.i.d. was established.
- 15 patients showed tumor progression, while 16 experienced stable disease.
- One patient with renal cell carcinoma achieved a partial response.
Takeaway
This study tested a new cancer drug called BAY 43-9006 to see if it is safe and helps fight cancer. It turned out to be safe and worked for some patients.
Methodology
This was a Phase I, open-label, noncontrolled, single-centre dose-escalation study where patients received BAY 43-9006 for 21 days followed by 7 days off.
Potential Biases
Potential bias due to the open-label design and lack of control group.
Limitations
The study was limited to a small sample size and was conducted at a single center.
Participant Demographics
All participants were Caucasian, with a median age of 58 years, and included both males and females.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website